GlassScriptPhysician profile
John L Huber
NPI 1700857315
$2,008.80
in general payments reported to CMS, 2019-2025
36 companies · $495 in 2025
The $495 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $150 · 2021: $112 · 2022: $166 · 2023: $243 · 2024: $678 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.57 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $266.86 | 2021-2025 | Reblozyl, Pomalyst, Breyanzi |
| Beigene USA, INC. | $196.09 | 2022-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $160.32 | 2022-2025 | |
| Pfizer INC. | $142.63 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.50 | 2019-2021 | |
| Abbvie INC. | $117.36 | 2024-2025 | |
| Daiichi Sankyo INC. | $110.11 | 2024-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $105.59 | 2020-2024 | Xospata |
| Astrazeneca Pharmaceuticals LP | $94.59 | 2020-2024 | Enhertu, Tagrisso |
| Novo Nordisk INC | $56.52 | 2024-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $50.91 | 2024-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $48.91 | 2022-2024 | Keytruda |
| Servier Pharmaceuticals LLC | $39.64 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $38.15 | 2025 | Onivyde |
| Gilead Sciences, INC. | $35.92 | 2021-2025 | Trodelvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.61 | 2021-2025 | Uplizna |
| Bayer Healthcare Pharmaceuticals INC. | $29.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $26.40 | 2025 | Blenrep |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.17 | 2019 | |
| Seagen INC. | $22.93 | 2023 | Padcev |
| Genentech USA, INC. | $22.76 | 2024 | Polivy |
| Sun Pharmaceutical Industries INC. | $22.70 | 2023 | Odomzo, Yonsa |
| Recordati_rare_diseases_inc. | $18.79 | 2025 | Panhematin |
| Dova Pharmaceuticals | $18.65 | 2021 | |
| Incyte Corporation | $18.34 | 2024 | Pemazyre, Monjuvi |
| Pharmaessentia USA Corporation | $18.18 | 2022 | |
| Puma Biotechnology, INC. | $17.60 | 2023 | |
| Acceleron Pharma, INC. | $17.47 | 2020 | |
| Kite Pharma, INC. | $17.44 | 2025 | Yescarta |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Springworks Therapeutics, INC. | $15.76 | 2024 | Ogsiveo |
| Morphosys, US INC. | $14.87 | 2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $12.92 | 2021 | |
| Global Blood Therapeutics, INC. | $11.42 | 2021 | |
| Biofrontera INC. | $10.26 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.